Research
Hormonal
Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.
Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.
LimitedSupportsHIGH confidence
In the wild-type-high-fat, high-carbohydrate model, we observed the most body weight loss in the EPGN2154+Sema combination group compared to the other treatment groups.
Why this rating
Preclinical animal models.
Source
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models
Jashdeep Bhattacharjee et al. · Hepatology Communications · 2023
DOI 10.1097/hc9.0000000000000323
mechanism_only · n=100Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →